Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword

Petakh, Pavlo; Kamyshna, Iryna; Nykyforuk, Andriy; Yao, Rouan; Imbery, John F.; Oksenych, Valentyn; Корда, М. М.; Kamyshnyі, Аleksandr

doi:10.3390/v14030477

Cited by 27 publications

(26 citation statements)

References 175 publications

(195 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leptospires are capable of altering gut microbiota. Similar mechanisms, according to which infectious agents change the gut microbiota, have also been revealed for SARS-CoV-2, Influenza, M. tuberculosis, and some other microorganisms (111)(112)(113)(114). Most of the current studies emphasize the possible influence of these microbiota changes on the course of diseases (115)(116)(117).…”

Section: Discussionsupporting

confidence: 59%

Weil's Disease - from Gut Dysbiosis to Immunopathogenesis and Multiple Organ Failure

Petakh¹,

Isevych²,

Oksenych³

2022

Preprint

View full text Add to dashboard Cite

Leptospirosis is an important zoonotic disease, causing about 60,000 deaths annually. One of the reasons for the severe course of leptospirosis is a cytokine storm, which develops as a result of an excessive immune response. The gut microbiota that resides in the gastrointestinal tract provides essential health benefits to its host, particularly by regulating immune homeostasis and a bidirectional relationship with many internal organs. A change in the gut microbiota can be caused not only by antibiotics, but also by infectious agents such as the coronavirus or the flu virus. It is known that L. interrogans can change the microbiota of mice. Thus, gut dysbiosis in leptospirosis can affect the clinical course of the disease, through the gut–organ axis. Modulation of intestinal microbiota by probiotics and/or fecal microbiota transplantation in leptospirosis may become an important area of scientific research.

show abstract

Section: Discussionsupporting

confidence: 59%

Weil's Disease - from Gut Dysbiosis to Immunopathogenesis and Multiple Organ Failure

Petakh¹,

Isevych²,

Oksenych³

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Comorbidity is also needed to be considered when conducting telerehabilitation studies for COVID-19. Studies found that hypertension and type 2 diabetes are the most common comorbidities, which may induce a more severe course of COVID-19 ( 56 , 60 , 61 ). Of the included studies, only three studies ( 22 , 23 , 32 ) measuring different outcomes reported comorbidities, which prevents further analysis of comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Do patients with and survivors of COVID-19 benefit from telerehabilitation? A meta-analysis of randomized controlled trials

Huang

Fan

Zhao

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundCoronavirus disease 2019 (COVID-19) significantly impacts physical, psychological, and social functioning and reduces quality of life, which may persist for at least 6 months. Given the fact that COVID-19 is a highly infectious disease and therefore healthcare facilities may be sources of contagion, new methods avoiding face-to-face contact between healthcare workers and patients are urgently needed. Telerehabilitation is the provision of rehabilitation services to patients at a distance via information and communication technologies. However, high-quality evidence of the efficacy of telerehabilitation for COVID-19 is still lacking. This meta-analysis aimed to investigate the efficacy of telerehabilitation for patients with and survivors of COVID-19.MethodsWe searched the Cochrane Library, EMBASE, Medline (via PubMed), PEDro, ClinicalTrials.gov, and WHO International Clinical Trials Registry Platform from January 1st, 2020 to April 30th, 2022 for randomized controlled trials published in English, which aimed to evaluate the efficacy of telerehabilitation vs. face-to-face rehabilitation, usual care, or no treatment for COVID-19. Methodological quality and overall evidence quality of the included studies were assessed. The statistical reliability of the data was quantified using the trial sequential analysis.ResultsSeven randomized controlled trials with eight comparisons were included and all of them were used for meta-analysis. The meta-analyses of absolute values showed the superiority of telerehabilitation over no treatment or usual care for dyspnea (Borg scale: mean difference = −1.88, −2.37 to −1.39; Multidimensional dyspnea-12: mean difference = −3.70, −5.93 to −1.48), limb muscle strength (mean difference = 3.29; 2.12 to 4.47), ambulation capacity (standardized mean difference = 0.88; 0.62 to 1.14), and depression (mean difference = −5.68; −8.62 to −2.74). Significant improvement in these variables persisted in the meta-analyses of change scores. No significant difference was found in anxiety and quality of life. No severe adverse events were reported in any of the included studies.ConclusionsModerate- to very low-quality evidence demonstrates that telerehabilitation may be an effective and safe solution for patients with and survivors of COVID-19 in dyspnea, lower limb muscle strength, ambulation capacity, and depression. Further well-designed studies are required to evaluate the long-term effects, cost-effectiveness, and satisfaction in larger samples.

show abstract

“…The most commonly used diabetes medications are metformin and insulin. Theoretical evidence suggests that metformin may be beneficial for reducing proinflammatory and profibrotic states ( 2 , 10 , 11 ) and improving immune response ( 12 ). Insulin treatment may increase the risk of poor prognosis by increasing renal Angiotensin Converting Enzyme 2 (ACE2) expression in diabetic mice ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

“…Coronavirus disease 2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), was first reported in December 2019 ( 1 , 2 ). The severity of COVID-19 ranges from asymptomatic to severe infection leading to death ( 1 ).…”

Section: Introductionmentioning

confidence: 99%

Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes

Petakh¹,

Griga²,

Mohammed³

et al. 2022

Med Arch

View full text Add to dashboard Cite

Background: COVID-19 infection caused by SARS-COV-2 can result in multi-organ injuries and significant mortality in severe and critical patients, particularly those with type 2 diabetes as a comorbidity. Metformin and insulin are the main diabetes medications that affect the outcome of patients with COVID-19. Objective: The purpose of our study was to find out the features of the hematological indicators of patients with COVID-19 patients and type 2 diabetes. Methods: This is a retrospective study of the hospital confirmed COVID-19 patients between January to March 2022, who were admitted to Transcarpathian Regional Clinical Infectious Diseases Hospital (Uzhhorod, Ukraine). Results: The effect of type 2 diabetes, metformin, and insulin on COVID-19 were analyzed, respectively. Demographics and blood laboratory indices were collected. In patients who took metformin, the level of CRP was significantly lower than in patients who did not take metformin (24 mg/L [IQR 15 - 58] vs 52 mg/L, [IQR 22–121], P = 0.046). Conclusion: Our findings suggest that pre-admission metformin use may benefit COVID-19 patients with type 2 diabetes.

show abstract

Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword

Cited by 27 publications

References 175 publications

Weil's Disease - from Gut Dysbiosis to Immunopathogenesis and Multiple Organ Failure

Weil's Disease - from Gut Dysbiosis to Immunopathogenesis and Multiple Organ Failure

Do patients with and survivors of COVID-19 benefit from telerehabilitation? A meta-analysis of randomized controlled trials

Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes

Contact Info

Product

Resources

About